Form 4: Theravance Biopharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Rick E Winningham, CHIEF EXECUTIVE OFFICER and a Director of Theravance Biopharma, Inc., reported a transaction in 20,034 shares of common stock on August 20, 2026.
Summary
- Tax/exercise-price withholding: disposed of 20,034 Ordinary Shares at $16.95 ($339,576) on August 20, 2026; holds 1,611,022 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rick E Winningham — Director, Officer (CHIEF EXECUTIVE OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Tax/exercise-price withholding | Ordinary Shares | 20,034 | $17 | $339.6K | 1,611,022 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Tax/exercise-price withholding (20,034 shares) |
Keywords
insider transaction, Form 4, TBPH, Theravance Biopharma, Inc., neutral, Rick E Winningham
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.